cinnabarinic acid has been researched along with 2,6-dihydroxyanthraquinone in 1 studies
| Studies (cinnabarinic acid) | Trials (cinnabarinic acid) | Recent Studies (post-2010) (cinnabarinic acid) | Studies (2,6-dihydroxyanthraquinone) | Trials (2,6-dihydroxyanthraquinone) | Recent Studies (post-2010) (2,6-dihydroxyanthraquinone) |
|---|---|---|---|---|---|
| 36 | 0 | 19 | 24 | 0 | 6 |
| Protein | Taxonomy | cinnabarinic acid (IC50) | 2,6-dihydroxyanthraquinone (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 1.1 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 3.8 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 5.62 | |
| Estrogen receptor beta | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lefin, R; Petzer, A; Petzer, JP | 1 |
1 other study(ies) available for cinnabarinic acid and 2,6-dihydroxyanthraquinone
| Article | Year |
|---|---|
Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
Topics: Anthraquinones; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phenothiazines; Structure-Activity Relationship | 2022 |